Olmesartan Medoxomilo + Hidroclorotiazida Jubilant (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil combined with hydrochlorothiazide is indicated for hypertension management within the renin‑angiotensin‑aldosterone system pathway.

• Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with fluid retention: provides additional diuretic effect to improve blood pressure control.
• High‑risk cardiovascular patients: assists in achieving target blood pressure when monotherapy is insufficient.

• Olmesartan medoxil selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth‑muscle and adrenal cells, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and further decreasing plasma volume, which together produce a synergistic antihypertensive effect.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Cough
• Increased urination
• Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Liver function abnormalities
• Blood dyscrasias such as agranulocytosis

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

• Renal function: evaluate baseline creatinine and eGFR.
• Electrolytes: check serum potassium and sodium levels.
• Hepatic function: monitor liver enzymes in patients with liver disease.
• Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
• Concomitant NSAIDs: use with caution as they may reduce antihypertensive effect.
• Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Olmesartan medoxil + hydrochlorothiazide may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

• Aliskiren (dual renin‑angiotensin system blockade increases risk of renal impairment).
• Potassium‑sparing diuretics or supplements (risk of hyperkalemia).
• Lithium (reduced clearance may lead to toxicity).

Moderate Interactions (Monitor Closely)

• NSAIDs (may blunt antihypertensive response and affect renal function).
• ACE inhibitors (combined use can cause additive hypotension and hyperkalemia).
• Antidiabetic agents (diuretic effect may enhance hypoglycaemia).